Advertisement

Drugs & Therapy Perspectives

, Volume 17, Issue 12, pp 12–15 | Cite as

Clinical and pharmacoeconomic aspects both play an important role in the treatment of ovarian cancer

Drug economics and QOL

Keywords

Ovarian Cancer Paclitaxel Colchicine Gout Amifostine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bodurka-Bevers D, Sun CC, Gershenson DM. Pharmacoeconomic considerations in treating ovarian cancer. Pharmacoeconomics 2000 Feb; 17(2): 133–50PubMedCrossRefGoogle Scholar
  2. 2.
    American Cancer Society. Statistics 2000: cancer facts and figures: selected cancers: ovary. Available from URL: http://www.cancer.org. Accessed on 16 Oct 2000
  3. 3.
    McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1–6PubMedCrossRefGoogle Scholar
  4. 4.
    McGuire W, Neugut AI, Arikian S, et al. Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer. J Clin Oncol 1997; 15(2): 640–5PubMedGoogle Scholar
  5. 5.
    Elit LM, Gafni A, Levine MN. Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective. J Clin Oncol 1997; 15(2): 632–9PubMedGoogle Scholar
  6. 6.
    Berger K, Fischer T, Szucs TD. Cost-effectiveness analysis of paclitaxel and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective. Eur J Cancer 1998; 34(12): 1894–901PubMedCrossRefGoogle Scholar
  7. 7.
    Doyle C, Stockier M, Pintilie M, et al. Resource implications of palliative chemotherapy for ovarian cancer. J Clin Oncol 1997; 15(3): 1000–7PubMedGoogle Scholar
  8. 8.
    Calhoun EA, Bennett CL. Pharmacoeconomics of amifostine in ovarian cancer. Semin Oncol 1999; 26(2 Suppl. 7): 102–7PubMedGoogle Scholar
  9. 9.
    Patnaik A, Doyle C, Oza AM. Palliative therapy in advanced ovarian cancer: balancing patient expectations, quality of life and cost. Anticancer Drugs 1998; 9: 869–78PubMedCrossRefGoogle Scholar
  10. 10.
    Ortega A, Dranitsaris G, Sturgen J, et al. Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer. Gynecol Oncol 1997; 66(3): 454–63PubMedCrossRefGoogle Scholar
  11. 11.
    Kornblith AB, Thaler HT, Wong G, et al. Quality of life of women with ovarian cancer. Gynecol Oncol 1995; 59(2): 231–42PubMedCrossRefGoogle Scholar
  12. 12.
    Portenoy FK, Kornblith AB, Wong G, et al. Pain in ovarian cancer patients: prevalence, characteristics, and associated symptoms. Cancer 1994; 74: 907–15PubMedCrossRefGoogle Scholar
  13. 13.
    Guidozzi F. Living with ovarian cancer. Gynecol Oncol 1993; 50: 202–7PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Personalised recommendations